For highly sensitive APIsTweet
Roquette announces the launch of PEARLITOL® 150 SD within the PEARLITOL® SD range, mannitol for direct compression and reference products in the global pharmaceutical market.
Developed specifically for APIs that are highly sensitive to reducing sugars, PEARLITOL® 150 SD enables advanced dosage forms, even when using 'difficult' active ingredients.
It guarantees low levels of reducing sugars - below 300 ppm - and does not affect the stability of reducing sugar-sensitive APIs.
It has a precise and controlled particle size distribution to ensure good processability and reliable dosage in every tablet.
The market launch of PEARLITOL® 150 SD, together with the other grades in the PEARLITOL® SD portfolio, opens up further possibilities for innovation in the pharmaceutical sector.
The PEARLITOL® Mannitol pharma range is used as a filler and binder, as well as bulk sweetener, and is characterised by exceptional physical and chemical stability and lack of hygroscopicity.
Using different texturisation technologies, PEARLITOL® is directly compressible (SD, DC and C) and flexible in dosage. PEARLITOL® is suitable for use in formulations intended for all types of patients, including paediatric and diabetic patients, and in various oral dosage forms in both pharmaceutical and nutraceutical applications: swallowable tablets, orally dispersible tablets, chewable tablets, effervescent tablets, tablets, mixtures, granules, pellets, premixes and medicated confectionery.
Roquette's products are distributed in Italy by Faravelli. Please send your info enquiry to: email@example.com